The retatrutide results demonstrated dose-dependent weight loss, with lower doses producing proportionally less but still clinically significant reductions
The regulator said the product submission, called Svemia, was filed by Canadian-based Apotex and is a generic version of the brand name drug Wegovy, sold by Denmark's Novo Nordisk
After 1:1 propensity score matching, measured baseline characteristics were well-balanced across treatment groups
Also, prior authorization is typically required
"While the rate of incidence of hair loss is still decidedly low, its a potential trade-off that a patient should consider." "Hair loss was reported more frequently in patients with greater weight loss (20%), suggesting that the events of hair loss were potentially related to the magnitude of weight loss." "Patient safety is of utmost importance to Novo Nordisk," the statement continued